fluorodeoxyglucose f18 has been researched along with MEA 2b in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arnous, MM; Lan, X; Sun, X | 1 |
Borrego-Dorado, I; Cuenca-Cuenca, JI; Gómez-Camarero, P; Navarro-González, E; Ortiz-de Tena, A; Ruiz-Franco-Baux, JV; Vázquez-Albertino, RJ | 1 |
2 other study(ies) available for fluorodeoxyglucose f18 and MEA 2b
Article | Year |
---|---|
Multiple Endocrine Neoplasia Type 2B Unmasked by 18 F-FDG PET/CT and 131 I-MIBG SPECT/CT.
Topics: 3-Iodobenzylguanidine; Adult; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Multiple Endocrine Neoplasia Type 2b; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Single Photon Emission Computed Tomography Computed Tomography; Thyroid Neoplasms | 2017 |
[Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].
Topics: Biomarkers, Tumor; Bone Neoplasms; Calcitonin; Carcinoma, Medullary; Disease Progression; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multiple Endocrine Neoplasia Type 2a; Multiple Endocrine Neoplasia Type 2b; Predictive Value of Tests; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Thyroid Neoplasms; Thyroidectomy | 2012 |